Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months. METHODS: We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination. The secondary end points of overall survival, investigator-assessed progression-free survival, independently assessed duration of response, and safety are reported. Sensitivity analyses were adjusted for patients who crossed over from placebo to pertuzumab after the interim analysis. RESULTS: The median overall survival was 56.5 months (95% confidence interval [CI], 49.3 to not reached) in the group receiving the pertuzumab combination, as compared with 40.8 months (95% CI, 35.8 to 48.3) in the group receiving the placebo combination (hazard ratio favoring the pertuzumab group, 0.68; 95% CI, 0.56 to 0.84; P<0.001), a difference of 15.7 months. This analysis was not adjusted for crossover to the pertuzumab group and is therefore conservative. Results of sensitivity analyses after adjustment for crossover were consistent. Median progression-free survival as assessed by investigators improved by 6.3 months in the pertuzumab group (hazard ratio, 0.68; 95% CI, 0.58 to 0.80). Pertuzumab extended the median duration of response by 7.7 months, as independently assessed. Most adverse events occurred during the administration of docetaxel in the two groups, with long-term cardiac safety maintained. CONCLUSIONS: In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination. (Funded by F. Hoffmann-La Roche and Genentech; CLEOPATRA ClinicalTrials.gov number, NCT00567190.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the safety and efficacy profiles for SC trastuzumab in combination with IV pertuzumab and docetaxel as a first-line treatment for patients with HER2-positive MBC in the MetaPHER study (NCT02402712) was found to be consistent with those observed for IV trastuzumab in combination with IV pertuzumab and docetaxel in the CLEOPATRA study (NCT00567190) [21, 35–38].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Self-citationGianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Self-citationSmith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Self-citationvon Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 676
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Self-citation
Cited by
Items 201–300 of 1,001
Hanker, A. B., Estrada, M. V., Bianchini, G., Moore, P. D., Zhao, J., Cheng, F., Koch, J. P., Gianni, L., Tyson, D. R., Sanchez, V. M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2808 · Cited by 108
The use of combinations of monoclonal antibodies in clinical oncology
Henricks, L. M., Schellens, J. H. M., Huitema, A. D. R., & Beijnen, J. H. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.10.008 · Cited by 106
Yu, S., Liu, Q., Han, X., Qin, S., Zhao, W., Li, A., & Wu, K. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0091-4 · Cited by 108
Weberpals, J. G., Jansen, L., Müller, O. J., & Brenner, H. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy167 · Cited by 110
Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer
Honkanen, T. J., Tikkanen, A., Karihtala, P., Mäkinen, M. J., Väyrynen, J. P., & Koivunen, J. P. (2019) · Scientific Reports · doi:10.1038/s41598-019-47375-2 · Cited by 103
Miles, D. W., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz‐Yablonski, T., Campone, M., Bondarenko, I., Nowecki, Z. I., Errihani, H. H., Paluch–Shimon, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.024 · Cited by 103
Self-citationTargeted Therapies for Brain Metastases from Breast Cancer
Venur, V. A., & Leone, J. P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091543 · Cited by 96
Ma, F., Yan, M., Li, W., Ouyang, Q., Tong, Z., Teng, Y., Wang, Y., Wang, S., Geng, C., Luo, T., et al. (2023) · BMJ · doi:10.1136/bmj-2023-076065 · Cited by 114
Fifty years of monoclonals: the past, present and future of antibody therapeutics
Chan, A. C., Martyn, G. D., & Carter, P. J. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01207-9 · Cited by 131
Oberg, H. H., Kellner, C., Gonnermann, D., Sebens, S., Bauerschlag, D., Gramatzki, M., Kabelitz, D., Peipp, M., & Wesch, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00814 · Cited by 95
Ishii, K., Morii, N., & Yamashiro, H. (2019) · Core evidence · doi:10.2147/ce.s217848 · Cited by 114
Shibata, H., Kato, S., Sekine, I., Abe, K., Araki, N., Iguchi, H., Izumi, T., Inaba, Y., Osaka, I., Kato, S., et al. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000037 · Cited by 97
Tóth, G., Szöőr, Á., Simon, L., Yarden, Y., Szöllõsi, J., & Vereb, G. (2016) · mAbs · doi:10.1080/19420862.2016.1204503 · Cited by 94
Consideration of breast cancer subtype in targeting the androgen receptor
Venema, C. M., Bense, R. D., Steenbruggen, T. G., Nienhuis, H. H., Qiu, S.-Q., van Kruchten, M., Brown, M. A., Tamimi, R. M., Hospers, G. A. P., Schroder, C. P., et al. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.005 · Cited by 96
Ponde, N. F., Ameye, L., Lambertini, M., Paesmans, M., Piccart, M. J., & de Azambuja, E. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.023 · Cited by 98
Perspectives of HER2-targeting in gastric and esophageal cancer
Gerson, J. N., Skariah, S., Denlinger, C. S., & Astsaturov, I. A. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1315406 · Cited by 100
Larionov, A. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00089 · Cited by 102
Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway
Wilks, S. T. (2015) · The Breast · doi:10.1016/j.breast.2015.06.002 · Cited by 102
Arena, S., Siravegna, G., Mussolin, B., Kearns, J. D., Wolf, B. B., Misale, S., Lazzari, L., Bertotti, A., Trusolino, L., Adjei, A. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5640 · Cited by 93
Addressing intra-tumoral heterogeneity and therapy resistance
Rybinski, B., & Yun, K. (2016) · Oncotarget · doi:10.18632/oncotarget.11875 · Cited by 107
Meattini, I., Becherini, C., Caini, S., Coles, C. E., Cortés, J., Curigliano, G., de Azambuja, E., Isacke, C. M., Harbeck, N., Kaidar‐Person, O., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00534-x · Cited by 99
Self-citationAntisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics
Le, B. T., Raguraman, P., Kosbar, T. R., Fletcher, S., Wilton, S. D., & Veedu, R. N. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.007 · Cited by 96
Li, Q., Guan, X., Chen, S., Yi, Z., Lan, B., Xing, P., Fan, Y., Wang, J., Luo, Y., Yuan, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4173 · Cited by 93
Fujimoto, Y., Morita, T., Ohashi, A., Haeno, H., Hakozaki, Y., Fujii, M., Kashima, Y., Kobayashi, S. S., & Mukohara, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-78646-y · Cited by 98
Failures in Phase III: Causes and Consequences
Seruga, B., Ocana, A., Amir, E., & Tannock, I. F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0124 · Cited by 88
Lang, G., Jiang, Y., Shi, J., Yang, F., Li, X., Pei, Y., Zhang, C., Ma, D., Xiao, Y., Hu, P.-C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19342-3 · Cited by 93
Research needs in breast cancer
Cardoso, F., Harbeck, N., Barrios, C. H., Bergh, J. C. S., Cortés, J., Saghir, M. Z., Francis, P. A., Hudis, C. A., Ohno, S., Partridge, A. H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw571 · Cited by 96
Self-citationEvolution of anti-HER2 therapies for cancer treatment
Parakh, S., Gan, H. K., Parslow, A. C., Burvenich, I. J. G., Burgess, A. W., & Scott, A. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.005 · Cited by 97
Twelves, C. J., Jové, M., Gombos, A., & Awada, A. H. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.021 · Cited by 100
Breast Cancer in Women Older Than 80 Years
Shachar, S. S., Hurria, A., & Muss, H. B. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.010207 · Cited by 91
ErbB2 signaling at the crossing between heart failure and cancer
Vermeulen, Z., Segers, V. F. M., & Keulenaer, G. W. D. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-016-0576-z · Cited by 92
Yabar, C. S., & Winter, J. M. (2016) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.04.003 · Cited by 94
HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development
Arab, A., Yazdian‐Robati, R., & Behravan, J. (2020) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-019-00566-1 · Cited by 96
Mazières, J., Lafitte, C., Ricordel, C., Greillier, L., Negre, E., Zalcman, G., Domblides, C., Madelaine, J., Bennouna, J., Mascaux, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01455 · Cited by 87
Huober, J., Holmes, E. M., Baselga, J. M., de Azambuja, E., Untch, M., Fumagalli, D., Sarp, S., Láng, I., Smith, I., Boyle, F. M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.038 · Cited by 82
Self-citationPhillips, C. M., Parmar, A., Guo, H., Schwartz, D., Isaranuwatchai, W., Beca, J. M., Dai, W. F., Arias, J., Gavura, S., & Chan, K. (2020) · Cancer · doi:10.1002/cncr.32697 · Cited by 91
Molecular Oncology of Breast Cancer
Joshi, H. N., & Press, M. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00022-2 · Cited by 97
HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer
Kubota, T., Kuroda, S., Kanaya, N., Morihiro, T., Aoyama, K., Kakiuchi, Y., Kikuchi, S., Nishizaki, M., Kagawa, S., Tazawa, H., et al. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.05.019 · Cited by 88
Crosby, E. J., Gwin, W. R., Blackwell, K., Marcom, P. K., Chang, S., Maecker, H. T., Broadwater, G., Hyslop, T., Kim, S., Rogatko, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3102 · Cited by 85
Self-citationHistology-agnostic drug development — considering issues beyond the tissue
Pestana, R. C., Sen, S., Hobbs, B. P., & Hong, D. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0384-0 · Cited by 87
Balachandran, V., Haritha, N. H., Vijayakurup, V., Shabna, A., Shah, S., Krishna, A., Pillai, K. S., Thankachan, S., & Anto, R. J. (2015) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.61 · Cited by 82
Optimal treatment of early stage HER2‐positive breast cancer
Pernas, S., Barroso‐Sousa, R., & Tolaney, S. M. (2018) · Cancer · doi:10.1002/cncr.31657 · Cited by 85
Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review
Ponde, N. F., Aftimos, P. G., & Piccart, M. J. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0633-6 · Cited by 86
Drug resistance in breast cancer: Mechanisms and strategies for management
Wu, G., Xiao, M., Hao, W.-C., Yang, Z., Liu, X., Xu, D., Peng, Z.-X., & Zhang, L. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101288 · Cited by 90
Qin, G., Xu, F., Qin, T., Zheng, Q., Shi, D., Xia, W., Tian, Y., Tang, Y., Wang, J., Xiao, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5993 · Cited by 81
Saad, E. D., & Buyse, M. E. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv562 · Cited by 87
Cardiotoxicity of cancer chemotherapy in clinical practice
Jain, D., & Aronow, W. S. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1530831 · Cited by 77
Breast cancer treatment-induced cardiotoxicity
Martel, S., Maurer, C., Lambertini, M., Ponde, N. F., & de Azambuja, E. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1351541 · Cited by 89
18F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer
Ulaner, G. A., Castillo, R., Goldman, D. A., Wills, J., Riedl, C. C., Pinker, K., Jochelson, M. S., & Gönen, M. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3402-9 · Cited by 80
Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
Rassy, E., Rached, L., & Pistilli, B. (2022) · The Breast · doi:10.1016/j.breast.2022.10.016 · Cited by 81
Martín-Castillo, B., Pernas, S., Dorca, J., Álvarez, I., Torres‐Martínez, S., Pérez-García, J. M., Batista-López, N., Rodríguez‐Sánchez, C. A., Amillano, K., Domínguez, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26286 · Cited by 78
Self-citationBreast cancer brain metastasis: Current evidence and future directions
Sun, H., Xu, J., Dai, S., Ma, Y., & Sun, T. (2022) · Cancer Medicine · doi:10.1002/cam4.5021 · Cited by 84
HER2 expression in urothelial carcinoma, a systematic literature review
Scherrer, E., Kang, A., Bloudek, L. M., & Koshkin, V. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1011885 · Cited by 87
Estrogen-Related Receptors in Breast Cancer and Prostate Cancer
Misawa, A., & Inoue, S. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00083 · Cited by 90
Perez, E. A., López-Vega, J. M., Petit, T., Zamagni, C., Easton, V., Kamber, J., Restuccia, E., & Andersson, M. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0773-6 · Cited by 76
Schneeweiß, A., Park‐Simon, T., Albanell, J., Lassen, U., Cortés, J., Dieras, V. C., May, M., Schindler, C., Marmé, F., Cejalvo, J. M., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0562-4 · Cited by 80
Self-citationClark, A. S., Yau, C. S. F., Wolf, D. M., Petricoin, E. F., Veer, L. V. ‘., Yee, D., Moulder, S. L., Wallace, A. M., Chien, A. J., Isaacs, C. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26019-y · Cited by 76
Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
Schlam, I. M., Tarantino, P., & Tolaney, S. M. (2022) · Cancers · doi:10.3390/cancers14163996 · Cited by 88
Claus, J., Patel, G. S., Autore, F., Colomba, A., Weitsman, G. E., Soliman, T. N., Roberts, S. K., Zanetti-Domingues, L. C., Hirsch, M., Collu, F., et al. (2018) · eLife · doi:10.7554/elife.32271 · Cited by 75
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors
Dieci, M. V., Miglietta, F., Griguolo, G., & Guarneri, V. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102064 · Cited by 82
Stroes, C. I., Schokker, S., Creemers, A., Molenaar, R. J., Hulshof, M. C. C. M., van der Woude, S. O., Bennink, R. J., Mathôt, R. A. A., Krishnadath, K. K., Punt, C. J. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01814 · Cited by 77
HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo
Hou, J., Zhou, Z., Chen, X., Zhao, R., Yang, Z., Wei, N., Ni, Q., Feng, Y., Yu, X., Ma, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9870 · Cited by 74
Watanabe, S., Yonesaka, K., Tanizaki, J., Nonagase, Y., Takegawa, N., Haratani, K., Kawakami, H., Hayashi, H., Takeda, M., Tsurutani, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.1995 · Cited by 78
Systemic therapy for metastatic HER2-positive breast cancer
Bredin, P., Walshe, J. M., & Denduluri, N. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.07.008 · Cited by 81
Shimoi, T., Nagai, S. E., Yoshinami, T., Takahashi, M., Arioka, H., Ishihara, M., Kikawa, Y., Koizumi, K., Kondo, N., Sagara, Y., et al. (2020) · Breast Cancer · doi:10.1007/s12282-020-01085-0 · Cited by 75
Hua, X., Bi, X.-W., Zhao, J.-L., Shi, Y.-X., Lin, Y., Wu, Z.-Y., Zhang, Y.-Q., Zhang, L.-H., Zhang, A.-Q., Huang, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3435 · Cited by 75
Ohba, A., Morizane, C., Ueno, M., Kobayashi, S., Kawamoto, Y., Komatsu, Y., Ikeda, M., Sasaki, M., Okano, N., Furuse, J., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0214 · Cited by 79
Biomarker assessment and molecular testing for prognostication in breast cancer
Kos, Z., & Dabbs, D. J. (2015) · Histopathology · doi:10.1111/his.12795 · Cited by 89
Delaloge, S., Pérol, D., Courtinard, C., Brain, E. G. C., Asselain, B. J. R., Bachelot, T., Debled, M., Dieras, V. C., Campone, M., Lévy, C., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw260 · Cited by 72
Self-citationDrug-biomarker co-development in oncology – 20 years and counting
Twomey, J. D., Brahme, N. N., & Zhang, B. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.002 · Cited by 83
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Stanowicka-Grada, M., & Senkus, E. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01137-5 · Cited by 79
Rubin, E., Shan, K. S., Dalal, S., Vu, D. U. D., Guaqueta, D. C., Naraine, A. M., & Ergle, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021064 · Cited by 85
Breast cancer complexity: implications of intratumoral heterogeneity in clinical management
Haynes, B. M., Sarma, A., Nangia‐Makker, P., & Shekhar, M. P. V. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9684-y · Cited by 77
Mouse models of breast cancer in preclinical research
Park, M. K., Lee, C. H., & Lee, H. (2018) · Laboratory Animal Research · doi:10.5625/lar.2018.34.4.160 · Cited by 73
Trastuzumab-Induced Cardiomyopathy
Barish, R. M. B., Gates, E., & Barac, A. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.07.005 · Cited by 81
Artificial intelligence-based biomarkers for treatment decisions in oncology
Ligero, M., Nahhas, O. S. M. E., Aldea, M. D., & Kather, J. N. (2025) · Trends in cancer · doi:10.1016/j.trecan.2024.12.001 · Cited by 84
Validated biomarkers: The key to precision treatment in patients with breast cancer
Duffy, M. J., O’Donovan, N., McDermott, E. W. M., & Crown, J. P. (2016) · The Breast · doi:10.1016/j.breast.2016.07.009 · Cited by 84
Neoadjuvant therapy for triple negative and HER2-positive early breast cancer
Harbeck, N., & Gluz, O. (2017) · The Breast · doi:10.1016/j.breast.2017.06.038 · Cited by 79
Tripathy, D., Brufsky, A., Cobleigh, M., Jahanzeb, M., Kaufman, P. A., Mason, G., O’Shaughnessy, J., Rugo, H. S., Swain, S. M., Yardley, D. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0446 · Cited by 71
Self-citationChinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022
CSCO BC guideline working group, Jiang, Z., Song, E., Geng, C., Pan, Y., Wang, X., Wang, H., Wang, S., Wang, X., Wu, J., et al. (2022) · Translational Breast Cancer Research · doi:10.21037/tbcr-22-21 · Cited by 81
Kurzeder, C., Bover, I., Marmé, F., Rau, J., Pautier, P., Colombo, N., Lorusso, D., Ottevanger, P. B., Bjurberg, M., Marth, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.0787 · Cited by 71
Müller, V., Nabieva, N., Häberle, L., Taran, F., Hartkopf, A. D., Volz, B., Overkamp, F., Brandl, A. L., Kolberg, H., Hadji, P., et al. (2017) · The Breast · doi:10.1016/j.breast.2017.08.008 · Cited by 69
Update on the Treatment of Early-Stage Triple-Negative Breast Cancer
Sharma, P. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0539-8 · Cited by 74
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Wynn, C., & Tang, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10021-x · Cited by 79
Rethinking breast cancer follow-up based on individual risk and recurrence management
Rose, F. D., Meduri, B., Santis, M. C. D., Ferro, A., Marino, L., Colciago, R. R., Gregucci, F., Vanoni, V., Apolone, G., Cosimo, S. D., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102434 · Cited by 73
Self-citationOvercoming Cancer Resistance: Strategies and Modalities for Effective Treatment
Koirala, M., & DiPaola, M. (2024) · Biomedicines · doi:10.3390/biomedicines12081801 · Cited by 75
Veeraraghavan, J., De Angelis, C., Reis-Filho, J. S., Pascual, T., Prat, A., Rimawi, M. F., Osborne, C. K., & Schiff, R. (2017) · The Breast · doi:10.1016/j.breast.2017.06.022 · Cited by 67
Shah, M., Wedam, S. B., Cheng, J., Fiero, M. H., Xia, H., Li, F., Fan, J., Zhang, X., Yu, J., Song, P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2701 · Cited by 71
McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66
HER family in cancer progression: From discovery to 2020 and beyond
Kumar, R., George, B., Campbell, M. R., Verma, N., Paul, A. M., Melo-Alvim, C., Ribeiro, L., Pillai, M. R., Costa, L., & Moasser, M. M. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.001 · Cited by 70
Lv, Q., Meng, Z., Yu, Y., Jiang, F., Guan, D., Liang, C., Zhou, J., Lü, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122095 · Cited by 66
Fietz, T., Tesch, H., Rauh, J., Boller, E., Kruggel, L., Jänicke, M., & Marschner, N. (2017) · The Breast · doi:10.1016/j.breast.2017.05.014 · Cited by 65
Alhussein, M. M., Mokbel, A. N., Cosman, T., Aghel, N., Yang, E. H., Mukherjee, S. D., Dent, S. F., Ellis, P. M., Dhesy‐Thind, S., & Leong, D. P. (2021) · CJC Open · doi:10.1016/j.cjco.2021.06.019 · Cited by 67
Application of aptamer-drug delivery system in the therapy of breast cancer
Fan, R., Tao, X., Zhai, X., Zhu, Y., Li, Y., Chen, Y., Dong, D., Yang, S., & Lv, L. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114444 · Cited by 74
The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyond
Kelly, C. M., & Janjigian, Y. Y. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.06.10 · Cited by 79
Li, T., Wang, C.-C., Zhang, L., & Chen, X. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac503 · Cited by 71
Zhang, C., Wang, S., Lu, X., Zhong, W., Tang, Y., Huang, W., Wu, F., Wang, X., Wei, W., & Tang, H. (2024) · Research · doi:10.34133/research.0472 · Cited by 88
Carvalho, S., Levi‐Schaffer, F., Sela, M., & Yarden, Y. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13450 · Cited by 72
Olaparib for the treatment of breast cancer
Griguolo, G., Dieci, M. V., Guarneri, V., & Conte, P. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1458613 · Cited by 72
Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began
Meisel, J. L., Venur, V. A., Gnant, M., & Carey, L. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201037 · Cited by 78
Metadata
- Authors
- Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., Clark, E., Ross, G., Benyunes, M. C., & Cortés, J.
- Affiliations
- MedStar Washington Hospital Center (US)
- Asan Medical Center (KR)
- National Cancer Center (KR)
- Institute of Oncology NN Petrov (RU)
- Hospital Universitario 12 De Octubre (ES)
- Centre Antoine Lacassagne (FR)
- University Hospital Heidelberg (DE)
- Roche (United Kingdom) (GB)
- Genentech (US)
- Vall d'Hebron Hospital Universitari (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-02-19
- Volume
- 372
- Issue
- 8
- Pages
- 724-734
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5584549
- OpenAlex
- W2137228442
- Cited by
- 2,164
- References
- 26
- Citations by year
- 2026: 138 · 2025: 150 · 2024: 157 · 2023: 197 · 2022: 191 · 2021: 212 · 2020: 206 · 2019: 217 · 2018: 202 · 2017: 207 · 2016: 197 · 2015: 87
- FWCI
- 100.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Tampere University Institutional Repository (Tampere University) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- Genentech
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- pertuzumab, trastuzumab, docetaxel, HER2-positive breast cancer, metastatic breast cancer, overall survival, progression-free survival, duration of response, cardiac safety, HER2-targeted therapy, first-line chemotherapy
- MeSH terms
- Trastuzumab, Docetaxel, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Infusions, Intravenous, Middle Aged, Neoplasm Metastasis, Survival Analysis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Taxoids, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.